ArticleOncology reports2019
miR‑505 suppresses prostate cancer progression by targeting NRCAM.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.Translational oncology · 2026Article
- The impact of neuron-related cell adhesion molecule on cellular biological functions and its clinical significance in small-cell lung cancer.Journal of thoracic disease · 2025Article
- HuR-induced circ_0082319 contributes to hepatocellular carcinoma by elevating PTK2 through miR-505-3p.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- CircNRCAM up-regulates NRCAM to promote papillary thyroid carcinoma progression.Journal of endocrinological investigation · 2024Article
- MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1.Cancer cell international · 2024Article
- Article
- Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.Cancer metastasis reviews · 2022Review
- A preliminary model of football-related neural stress that integrates metabolomics with transcriptomics and virtual reality.iScience · 2022Article
- KLF9 regulates miR-338-3p/NRCAM axis to block the progression of osteosarcoma cells.Journal of Cancer · 2022Article
- Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression.Cancer research · 2021Article
- Integrating multi-omics with neuroimaging and behavior: A preliminary model of dysfunction in football athletes.Neuroimage. Reports · 2021Article
- Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.Cancer cell international · 2021Article
- miR-505 inhibits proliferation of osteosarcoma via HMGB1.FEBS open bio · 2020Article
- MicroRNA-505, Suppressed by Oncogenic Long Non-coding RNA LINC01448, Acts as a Novel Suppressor of Glycolysis and Tumor Progression Through Inhibiting HK2 Expression in Pancreatic Cancer.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous researchers have demonstrated that microRNA‑505 (miR‑505) is negatively correlated with progression in various malignancies. However, the detailed function and molecular mechanisms of miR‑505 have yet to be completely elucidated in prostate cancer (PCa). The present study initially identified the potential role of miR‑505 in PCa using in vitro experiments, and demonstrated that restoration of miR‑505 inhibited proliferation, invasion and migration, yet induced cell cycle arrest and promoted apoptosis in PCa cells. The present study also demonstrated that the expression of neuron‑glial‑related cell adhesion molecule (NRCAM) was markedly upregulated in PCa cells when compared with benign prostate epithelium. A luciferase reporter assay demonstrated that miR‑505 directly targeted NRCAM in PCa cells. In addition, NRCAM stimulation antagonized the inhibitory effects of miR‑505 on the proliferation, migration, and invasion of PCa cells. Furthermore, lower levels of miR‑505 and higher levels of NRCAM may serve as a predictor of worse biochemical recurrence‑free survival or disease‑free survival in patients with PCa. In conclusion, the present study revealed the inhibitory effects of miR‑505 on PCa tumorigenesis, which potentially occur by targeting NRCAM. The combined analysis of NRCAM and miR‑505 may predict disease progression in patients with PCa following radical prostatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.